{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T03:26:25Z","timestamp":1791516385609,"version":"4.3.4"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1097\/md.0000000000000066","type":"journal-article","created":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T03:47:23Z","timestamp":1409888843000},"page":"e66","source":"Crossref","is-referenced-by-count":69,"title":["Risk Factors of Hyperammonemia in Patients With Epilepsy Under Valproic Acid Therapy"],"prefix":"10.1097","volume":"93","author":[{"given":"Yu-Lung","family":"Tseng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ren","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Hsiang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan-Ting","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng-Hsien","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Ching","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiung-Chih","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Neng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yao-Chung","family":"Chuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-2-20210226","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/0002-9343(88)90055-1","article-title":"Side effects of valproate.","volume":"84","author":"Dreifuss","year":"1988","journal-title":"Am J Med"},{"key":"R2-2-20210226","first-page":"494","article-title":"The measurement of ammonia blood levels in patients taking valproic acid: looking for problems where they do not exist Epilepsy Behav.","volume":"12","author":"Nicolai","year":"2008","journal-title":""},{"key":"R3-2-20210226","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archneur.1982.00510210061016","article-title":"Asymptomatic hyperammonemia in patients receiving valproic acid.","volume":"39","author":"Murphy","year":"1982","journal-title":"Arch Neurol"},{"key":"R4-2-20210226","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/00007691-198507030-00009","article-title":"Chronic valproic acid therapy and incidence of increases in venous plasma ammonia.","volume":"7","author":"Haidukewych","year":"1985","journal-title":"Ther Drug Monit"},{"key":"R5-2-20210226","first-page":"663","article-title":"Blood ammonia level during valproic acid therapy.","volume":"40","author":"Kugoh","year":"1986","journal-title":"Jpn J Psychiatry Neurol"},{"key":"R6-2-20210226","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.eplepsyres.2012.04.001","article-title":"Risk factors for hyperammonemia associated with valproic acid therapy in adult epilepsy patients.","volume":"101","author":"Yamamoto","year":"2012","journal-title":"Epilepsy Res"},{"key":"R7-2-20210226","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s00467-011-1838-5","article-title":"Hyperammonemia in review: pathophysiology, diagnosis, and treatment.","volume":"27","author":"Auron","year":"2012","journal-title":"Pediatr Nephrol"},{"key":"R8-2-20210226","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.genhosppsych.2010.10.004","article-title":"The real mechanism of VPA-induced hyperammonemia remains unknown.","volume":"33","author":"Hung","year":"2011","journal-title":"Gen Hosp Psychiatry"},{"key":"R9-2-20210226","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jhep.2010.11.031","article-title":"New insights on the mechanisms of valproate-induced hyperammonemia: inhibition of hepatic N-acetylglutamate synthase activity by valproyl-CoA.","volume":"55","author":"Aires","year":"2011","journal-title":"J Hepatol"},{"key":"R10-2-20210226","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1111\/epi.12125","article-title":"Risk factors for hyperammonemia in pediatric patients with epilepsy.","volume":"54","author":"Yamamoto","year":"2013","journal-title":"Epilepsia"},{"key":"R11-2-20210226","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1177\/0883073810377235","article-title":"Blood ammonia levels in epileptic children on 2 dose ranges of valproic acid monotherapy: a cross-sectional study.","volume":"26","author":"Sharma","year":"2011","journal-title":"J Child Neurol"},{"key":"R12-2-20210226","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.eplepsyres.2009.04.002","article-title":"The risk of asymptomatic hyperammonemia in children with idiopathic epilepsy treated with valproate: relationship to blood carnitine status.","volume":"86","author":"Hamed","year":"2009","journal-title":"Epilepsy Res"},{"key":"R13-2-20210226","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1111\/j.1528-1157.1989.tb05316.x","article-title":"Commission on Classification and Terminology of the International League Against Epilepsy.","volume":"30","year":"1989","journal-title":"Epilepsia"},{"key":"R14-2-20210226","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"R15-2-20210226","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1111\/j.1528-1167.2011.03316.x","article-title":"Effects of long-term antiepileptic drug monotherapy on vascular risk factors and atherosclerosis.","volume":"53","author":"Chuang","year":"2012","journal-title":"Epilepsia"},{"key":"R16-2-20210226","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1111\/j.1528-1167.2009.02303.x","article-title":"Hyperhomocysteinemia in epileptic patients on new antiepileptic drugs.","volume":"51","author":"Belcastro","year":"2010","journal-title":"Epilepsia"},{"key":"R17-2-20210226","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.kjms.2011.06.005","article-title":"Transient hyperammonemia associated with postictal state in generalized convulsion.","volume":"27","author":"Liu","year":"2011","journal-title":"Kaohsiung J Med Sci"},{"key":"R18-2-20210226","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/088307389701200709","article-title":"Asymptomatic hyperammonemia in children treated with valproic acid.","volume":"12","author":"Altunbasak","year":"1997","journal-title":"J Child Neurol"},{"key":"R19-2-20210226","doi-asserted-by":"crossref","first-page":"275","DOI":"10.3949\/ccjm.50.3.275","article-title":"Valproate-induced hyperammonemia in asymptomatic children.","volume":"50","author":"Wyllie","year":"1983","journal-title":"Cleve Clin Q"},{"key":"R20-2-20210226","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MEJ.0b013e32832c7b18","article-title":"Severe valproic acid intoxication: case study on the unbound fraction and the applicability of extracorporeal elimination.","volume":"16","author":"van den Broek","year":"2009","journal-title":"Eur J Emerg Med"},{"key":"R21-2-20210226","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1600-0404.2006.00793.x","article-title":"Non-convulsive status epilepticus secondary to valproic acid-induced hyperammonemic encephalopathy.","volume":"116","author":"Velioglu","year":"2007","journal-title":"Acta Neurol Scand"},{"key":"R22-2-20210226","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1111\/j.1528-1157.2000.tb00263.x","article-title":"Valproic acid-induced hyperammonemic encephalopathy with triphasic waves.","volume":"41","author":"Kifune","year":"2000","journal-title":"Epilepsia"},{"key":"R23-2-20210226","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1212\/WNL.54.1.230","article-title":"Valproate-induced hyperammonemic encephalopathy in the presence of topiramate.","volume":"54","author":"Hamer","year":"2000","journal-title":"Neurology"},{"key":"R24-2-20210226","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1097\/chi.0b013e31802ed8b2","article-title":"Case report: valproic acid and risperidone treatment leading to development of hyperammonemia and mania.","volume":"46","author":"Carlson","year":"2007","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"R25-2-20210226","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1046\/j.1528-1157.2002.13001.x","article-title":"The importance of drug interactions in epilepsy therapy.","volume":"43","author":"Patsalos","year":"2002","journal-title":"Epilepsia"},{"key":"R26-2-20210226","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1111\/j.1442-200X.2010.03157.x","article-title":"Effect of CPS14217CA genotype on valproic-acid-induced hyperammonemia.","volume":"52","author":"Yagi","year":"2010","journal-title":"Pediatr Int"},{"key":"R27-2-20210226","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2710.2008.00943.x","article-title":"Adjunctive topiramate enhances the risk of hypothermia associated with valproic acid therapy.","volume":"33","author":"Knudsen","year":"2008","journal-title":"J Clin Pharm Ther"},{"key":"R28-2-20210226","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1046\/j.1528-1157.2002.42401.x","article-title":"Topiramate enhances the risk of valproate-associated side effects in three children.","volume":"43","author":"Longin","year":"2002","journal-title":"Epilepsia"},{"key":"R29-2-20210226","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1176\/ajp.2007.164.7.1020","article-title":"Hyperammonemia due to valproic acid in the psychiatric setting.","volume":"164","author":"Carr","year":"2007","journal-title":"Am J Psychiatry"},{"key":"R30-2-20210226","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1176\/appi.neuropsych.10100151","article-title":"Hyperammonemia associated with valproic acid use in elderly psychiatric patients.","volume":"24","author":"Holroyd","year":"2012","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"R31-2-20210226","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/09674845.2008.11732816","article-title":"Influence of stable, long-term treatment with phenobarbital on the activity of serum alanine aminotransferase and gamma-glutamyltransferase.","volume":"65","author":"Lippi","year":"2008","journal-title":"Br J Biomed Sci"},{"key":"R32-2-20210226","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1007\/BF00450552","article-title":"The influence of long-term anticonvulsant therapy with diphenylhydantoin and carbamazepine on serum gamma-glutamyltransferase, aspartate aminotransferase, alanine aminotransferase and alkaline phosphatase.","volume":"237","author":"Aldenhovel","year":"1988","journal-title":"Eur Arch Psychiatry Neurol Sci"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000000066","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,2]],"date-time":"2024-06-02T07:07:03Z","timestamp":1717312023000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005792-201409010-00002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9]]},"references-count":32,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000000066","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2014,9]]}}}